LAMPRENE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LAMPRENE (LAMPRENE).
Clofazimine binds preferentially to mycobacterial DNA, inhibiting replication and exerting antimicrobial activity. It also has anti-inflammatory properties by modulating immune responses.
| Metabolism | Hepatic metabolism, primarily via unknown pathways; does not significantly induce or inhibit cytochrome P450 enzymes. |
| Excretion | Primarily fecal (unabsorbed drug and biliary excretion); renal excretion accounts for <1% of the dose as unchanged drug and metabolites. |
| Half-life | Terminal elimination half-life ranges from 8 to 70 days (mean approximately 14 days) due to extensive tissue storage and slow release; may be longer with chronic dosing. |
| Protein binding | Approximately 70-80% bound to plasma proteins, primarily albumin and lipoproteins. |
| Volume of Distribution | Extremely high, approximately 20 L/kg, indicating extensive tissue accumulation, particularly in adipose tissue and the reticuloendothelial system. |
| Bioavailability | Oral bioavailability is variable and incomplete, approximately 45-60% due to poor aqueous solubility; food enhances absorption (higher bioavailability with fatty meals). |
| Onset of Action | 2-4 weeks for clinical improvement in leprosy (oral); onset in erythema nodosum leprosum (ENL) may be slower. |
| Duration of Action | Prolonged due to slow elimination; duration of single dose effect not well-defined; clinical effects persist for weeks to months after cessation due to tissue accumulation. |
300 mg orally once daily in combination with other antimycobacterial agents.
| Dosage form | CAPSULE |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh class C). |
| Pediatric use | 5-6 mg/kg (up to 300 mg) orally once daily. |
| Geriatric use | No specific adjustment; use standard adult dosing with monitoring for adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LAMPRENE (LAMPRENE).
| Breastfeeding | Clofazimine is excreted into human breast milk. The milk-to-plasma (M/P) ratio is approximately 0.3–2.3, with significant interindividual variability. Infant exposure may be high enough to cause skin discoloration and other adverse effects. Breastfeeding is generally not recommended during therapy due to potential for infant toxicity, including skin pigmentation and gastrointestinal effects. |
| Teratogenic Risk | Clofazimine (Lamprene) is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxicity and teratogenicity at high doses. In humans, limited data suggest potential risks including fetal growth restriction and possible congenital anomalies. First trimester exposure may be associated with an increased risk of malformations; second and third trimester exposure may cause fetal skin discoloration (pink-brown) and other adverse effects. Use only if benefit clearly outweighs risk. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to clofazimine","Severe hepatic impairment","Pregnancy (only if benefit outweighs risk; avoid during first trimester)"]
| Precautions | ["Gastrointestinal toxicity: severe abdominal pain, obstruction, or bleeding (potentially fatal)","Skin discoloration: reddish-brown pigmentation (reversible upon discontinuation)","Ocular effects: conjunctival and corneal discoloration","Hepatotoxicity","Prolonged QT interval (risk of arrhythmias)"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal liver function tests (LFTs), renal function, CBC, and electrocardiogram (QTc interval) periodically. Assess fetal growth via ultrasound; consider monitoring for fetal skin discoloration or other anomalies. Newborns should be observed for skin pigmentation, gastrointestinal disturbances, and any signs of toxicity. |
| Fertility Effects | Clofazimine has not been well-studied for effects on human fertility. Animal studies at high doses have shown reversible effects on spermatogenesis and ovarian function. In humans, no definitive evidence of impaired fertility; however, men may experience reduced sperm count or motility, and women may have menstrual irregularities. Effects are likely reversible upon discontinuation. |